Literature DB >> 7494550

Cell-cell and cell-matrix adhesion molecules in human heart and lung transplants.

G Steinhoff1, A Haverich.   

Abstract

The interaction of immune cells with endothelial and target cells and extracellular matrix in human organ transplants is regulated by a number of receptor-ligand molecules. The molecules mediating intercellular adhesion and activation are classified as integrin, immunoglobulin and selectin families. In the present study the patterns of their cellular expression in human heart and lung transplants are described in normal state and during transplant rejection. The results reveal an organ specific regulation of the different adhesion molecules during transplant rejection. Specific differences were noted in the endothelial expression of vascular ligand molecules in the vascular segments of heart and lung transplants, especially in the lung capillaries. Cell type specific patterns of intercellular and cell-matrix adhesion molecules as their ligands were found in different states of graft rejection. Intravascular and interstitial differences in the expression patterns of leukocyte adhesion receptors support a concept of their stepwise function during graft infiltration. The implications for the organ specific appearance of inflammatory reactions in human heart and lung transplants as for immunosuppressive therapy are discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7494550     DOI: 10.1007/bf00944779

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  29 in total

Review 1.  Preservation and reperfusion injuries in liver allografts. An overview and synthesis of current studies.

Authors:  P A Clavien; P R Harvey; S M Strasberg
Journal:  Transplantation       Date:  1992-05       Impact factor: 4.939

2.  Monoclonal antibodies against intercellular adhesion molecule 1 prolong cardiac allograft survival in cynomolgus monkeys.

Authors:  T Flavin; K Ivens; R Rothlein; R Faanes; C Clayberger; M Billingham; V A Starnes
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

3.  Cell adhesion. Sticky sugars for selectins.

Authors:  T A Springer; L A Lasky
Journal:  Nature       Date:  1991-01-17       Impact factor: 49.962

4.  Protective effects of oligosaccharides in P-selectin-dependent lung injury.

Authors:  M S Mulligan; J C Paulson; S De Frees; Z L Zheng; J B Lowe; P A Ward
Journal:  Nature       Date:  1993-07-08       Impact factor: 49.962

5.  Effect of recovery from ischemic injury on class I and class II MHC antigen expression.

Authors:  C R Shackleton; S L Ettinger; M G McLoughlin; C H Scudamore; R R Miller; P A Keown
Journal:  Transplantation       Date:  1990-03       Impact factor: 4.939

6.  Monoclonal antibodies against LFA-1 and VLA-4 inhibit graft vasculitis in rat cardiac allografts.

Authors:  L C Paul; A Davidoff; D W Paul; H Benediktsson; T B Issekutz
Journal:  Transplant Proc       Date:  1993-02       Impact factor: 1.066

7.  Intercellular immune adhesion molecules in human liver transplants: overview on expression patterns of leukocyte receptor and ligand molecules.

Authors:  G Steinhoff; M Behrend; B Schrader; R Pichlmayr
Journal:  Hepatology       Date:  1993-08       Impact factor: 17.425

8.  Functional results after lung retransplantation.

Authors:  A Haverich; S W Hirt; T Wahlers; H J Schäfers; C Zink; H G Borst
Journal:  J Heart Lung Transplant       Date:  1994 Jan-Feb       Impact factor: 10.247

9.  Expression patterns of leukocyte adhesion ligand molecules on human liver endothelia. Lack of ELAM-1 and CD62 inducibility on sinusoidal endothelia and distinct distribution of VCAM-1, ICAM-1, ICAM-2, and LFA-3.

Authors:  G Steinhoff; M Behrend; B Schrader; A M Duijvestijn; K Wonigeit
Journal:  Am J Pathol       Date:  1993-02       Impact factor: 4.307

10.  Antibody against leukocyte integrin (CD18) prevents reperfusion-induced lung vascular injury.

Authors:  M J Horgan; S D Wright; A B Malik
Journal:  Am J Physiol       Date:  1990-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.